TNG908
Sponsors
Tango Therapeutics Inc., Tango Therapeutics, Inc.
Conditions
"Ph1:
•Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors
•MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM)
Ph2:
A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC
A2:LA or met.MTAP-del. mesothelioma
A3:LA or met.MTAP-del. sarcoma
A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology
A5:Other LA or met.MTAP-del. solid tumors
A6:MTAP-del. R/R GBM"Locally Advanced Solid Tumor
Phase 1
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
TerminatedNCT05275478
Start: 2022-03-23End: 2025-12-30Updated: 2026-04-15
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety,
Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients
with MTAP-deleted Advanced or Metastatic Solid Tumors
CompletedCTIS2024-511976-34-00
Start: 2022-10-31End: 2025-11-19Target: 50Updated: 2025-07-24